<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006665.pub2" GROUP_ID="WOUNDS" ID="289606062017060526" MERGED_FROM="" MODIFIED="2013-11-13 16:17:16 +0000" MODIFIED_BY="Sally Bell-Syer" REVIEW_NO="124" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2013-11-13 16:17:16 +0000" MODIFIED_BY="Sally Bell-Syer">
<TITLE>Vitamin C for preventing and treating tetanus</TITLE>
<CONTACT MODIFIED="2013-11-13 16:17:16 +0000" MODIFIED_BY="Sally Bell-Syer"><PERSON ID="B45E8D7D82E26AA2000223243A3234EC" ROLE="AUTHOR"><FIRST_NAME>Harri</FIRST_NAME><LAST_NAME>Hemilä</LAST_NAME><SUFFIX>PhD, MD</SUFFIX><POSITION>Docent, Associate Professor</POSITION><EMAIL_1>harri.hemila@helsinki.fi</EMAIL_1><URL>www.ltdk.helsinki.fi/users/hemila/</URL><MOBILE_PHONE>+358 9 041 532 9987</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Public Health, POB 41</DEPARTMENT><ORGANISATION>University of Helsinki</ORGANISATION><ADDRESS_1>Mannerheimintie 172</ADDRESS_1><CITY>Helsinki</CITY><ZIP>FIN-00014</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 9 191 27573</PHONE_1><FAX_1>+358 9 191 27570</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-11-13 16:17:16 +0000" MODIFIED_BY="Sally Bell-Syer"><PERSON ID="B45E8D7D82E26AA2000223243A3234EC" ROLE="AUTHOR"><FIRST_NAME>Harri</FIRST_NAME><LAST_NAME>Hemilä</LAST_NAME><SUFFIX>PhD, MD</SUFFIX><POSITION>Docent, Associate Professor</POSITION><EMAIL_1>harri.hemila@helsinki.fi</EMAIL_1><URL>www.ltdk.helsinki.fi/users/hemila/</URL><MOBILE_PHONE>+358 9 041 532 9987</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Public Health, POB 41</DEPARTMENT><ORGANISATION>University of Helsinki</ORGANISATION><ADDRESS_1>Mannerheimintie 172</ADDRESS_1><CITY>Helsinki</CITY><ZIP>FIN-00014</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 9 191 27573</PHONE_1><FAX_1>+358 9 191 27570</FAX_1></ADDRESS></PERSON><PERSON ID="14D879F682E26AA20003EB8A6559B647" ROLE="AUTHOR"><FIRST_NAME>Teija</FIRST_NAME><LAST_NAME>Koivula</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>teija.koivula@kotikone.fi</EMAIL_1><ADDRESS><DEPARTMENT>Department of Public Health, POB 41</DEPARTMENT><ORGANISATION>University of Helsinki</ORGANISATION><ADDRESS_1>Mannerheimintie 172</ADDRESS_1><CITY>Helsinki</CITY><ZIP>FIN-00014</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 504108825</PHONE_1><FAX_1>+358 9 19127570</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-11-13 15:51:33 +0000" MODIFIED_BY="Harri Hemilä">
<UP_TO_DATE>
<DATE DAY="16" MONTH="6" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="5" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="4" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2013-11-13 15:50:52 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-11-13 15:50:47 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Third update, new search, no new trials identified. No change to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-11-13 15:50:52 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Text updated, change from the estimation of vitamin C effect from the Mantel-Haenszel RR to the Peto OR. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-06-06 08:28:34 +0100" MODIFIED_BY="Harri Hemilä">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-06-06 08:28:34 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>Second update, new search, no new trials identified, conclusions not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-08-26 10:06:50 +0100" MODIFIED_BY="Harri Hemilä">
<DATE DAY="19" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>New search, no new trials identified, conclusions not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-01-06 15:41:03 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Contact details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-08-26 10:06:49 +0100" MODIFIED_BY="Harri Hemilä">
<DATE DAY="6" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="15" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-08-26 13:59:59 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2011-08-26 13:59:59 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-08-26 13:59:59 +0100" MODIFIED_BY="[Empty name]">
<NAME>NIHR/Department of Health (England), (Cochrane Wounds Group)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-11-13 16:06:26 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-06-14 06:22:09 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-08-06 16:51:29 +0100" MODIFIED_BY="[Empty name]">Vitamin C for preventing and treating tetanus</TITLE>
<SUMMARY_BODY MODIFIED="2013-06-14 06:22:09 +0100" MODIFIED_BY="[Empty name]">
<P>Tetanus is a disease caused by tetanus toxin, which is produced by the bacterium <I>Clostridium tetani</I>. This bacterium typically infects penetrating wounds contaminated by foreign material such as soil. In developing countries, poor hygiene after childbirth may cause tetanus in newborn babies. Even though vaccination has dramatically decreased the burden of tetanus, there are still about 1 million tetanus cases per year globally. We found one controlled trial that examined whether one gram per day of intravenous vitamin C would help in the treatment of tetanus patients. Vitamin C was used alongside standard treatments for tetanus. Intravenous vitamin C reduced the mortality of children aged between 1 and 12 with tetanus by 100% and that of 13 to 30 year old patients by 45%. The trial was not properly conducted and caution is required in the interpretation of the findings. Vitamin C cannot be recommended as a treatment for tetanus on the basis of this single study. Further investigation of the role of vitamin C in tetanus treatment is warranted.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-11-13 15:53:06 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-06-16 19:05:16 +0100" MODIFIED_BY="[Empty name]">
<P>Tetanus is a severe disease that can be prevented by vaccination. In developing countries vaccination coverage is not always high. Cases still occur also in developed countries, particularly in elderly people owing to their reduced immuno protection. There are about 1 million tetanus cases per year globally. In animal studies, vitamin C has protected against various infections and bacterial toxins. In a study with rats, vitamin C protected against the purified tetanus toxin.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-10-30 12:46:05 +0000" MODIFIED_BY="Harri Hemilä">
<P>To assess the prophylactic and therapeutic effect of vitamin C on tetanus.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-07-19 17:14:38 +0100" MODIFIED_BY="[Empty name]">
<P>In May 2013 we searched the Cochrane Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>); Ovid MEDLINE; Ovid MEDLINE (In-Process &amp; Other Non-Indexed Citations ); and Ovid EMBASE for this third update.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-11-13 15:52:40 +0000" MODIFIED_BY="[Empty name]">
<P>Controlled trials of vitamin C as a prevention or treatment for tetanus, whether or not these were placebo controlled, in any language, published or unpublished. Two review authors independently made inclusion decisions.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-11-13 15:53:06 +0000" MODIFIED_BY="Harri Hemilä">
<P>Both review authors independently extracted data from trial reports and assessed methodological quality. Since one of the cells in a 2 × 2 table had no events, we calculated the odds ratio (OR) and its 95% confidence interval (CI) for case fatality rate by using the Peto-method. Another of the 2 × 2 tables had no empty cells and the inverse-variance method was used to calculate its risk ratio (RR) estimate and 95% CI. We also used the Fisher's exact test to calculate the exact 95% CI for the OR of the 2 × 2 table with the empty cell.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-09-05 14:09:58 +0100" MODIFIED_BY="Harri Hemilä">
<P>One single trial was eligible for inclusion. This non-randomised, unblinded, controlled trial undertaken in Bangladesh involved 117 tetanus patients. Vitamin C at a dosage of 1 g/day was administered intravenously alongside conventional treatment. At recruitment, the participants were stratified into two age groups and the results were reported by age. There was a significant difference in the vitamin C effect between the two age groups (P = 0.01). In the tetanus patients aged 1 to 12 years (n = 62), vitamin C treatment was associated with a 100% reduction in case fatality rate (95% CI from -100% to -94%). In patients aged 13 to 30 years (n = 55), vitamin C treatment was associated with a 45% reduction in case fatality rate (95% CI from -69% to -5%).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-09-12 07:09:59 +0100" MODIFIED_BY="[Empty name]">
<P>A single, non-randomised, poorly reported trial of vitamin C as a treatment for tetanus suggests a considerable reduction in mortality. However, concerns about trial quality mean that this result must be interpreted with caution and vitamin C cannot be recommended as a treatment for tetanus on the basis of this evidence. New trials should be carried out to examine the effect of vitamin C on tetanus treatment.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-11-13 16:06:26 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-09-12 07:34:07 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-09-12 07:07:05 +0100" MODIFIED_BY="[Empty name]">
<P>'Tetanus' denotes a disease caused by tetanus toxin (tetanospasmin), a protein that is produced by the anaerobic bacterium <I>Clostridium tetani</I>. Although the pathological definition of tetanus is based on the specified bacterium and its toxin, the diagnosis is made clinically. The clinical picture is dominated by muscle spasms and rigidity. Often the first sign is rigidity of the jaw muscles, followed by stiffness of the neck, difficulty in swallowing, and rigidity of the abdominal muscles. Other symptoms include elevated temperature, raised blood pressure, and an episodically rapid heart rate. Tetanus may lead to complications such as fractures of the spine or long bones because of contractions and convulsions, and to pulmonary embolism, bed sores and nosocomial infections due to prolonged hospitalisation. The current treatment of tetanus consists, for example, of surgical debridement of the wound and antibiotic therapy (metronidazole) to remove the source of infection, tetanus immune globulin to neutralize circulating toxin, and benzodiazepine for sedation and muscle relaxation (<LINK REF="REF-Thwaites-2006" TYPE="REFERENCE">Thwaites 2006</LINK>; <LINK REF="REF-Gibson-2009" TYPE="REFERENCE">Gibson 2009</LINK>; <LINK REF="REF-Reddy-2010" TYPE="REFERENCE">Reddy 2010</LINK>; <LINK REF="REF-Afshar-2011" TYPE="REFERENCE">Afshar 2011</LINK>; <LINK REF="REF-Ataro-2011" TYPE="REFERENCE">Ataro 2011</LINK>; <LINK REF="REF-CDC-2013" TYPE="REFERENCE">CDC 2013</LINK>; <LINK REF="REF-WHO-2013" TYPE="REFERENCE">WHO 2013</LINK>).</P>
<P>Tetanus is typically caused by anaerobic bacterial growth in a contaminated penetrating wound. Vaccination against tetanus has dramatically reduced the incidence of the disease in developed countries, but infrequent cases occur, particularly in elderly people owing to reduced immuno protection (<LINK REF="REF-Gergen-1995" TYPE="REFERENCE">Gergen 1995</LINK>; <LINK REF="REF-Yuan-1997" TYPE="REFERENCE">Yuan 1997</LINK>). Nevertheless, about 1 million cases of tetanus are reported worldwide annually (<LINK REF="REF-Afshar-2011" TYPE="REFERENCE">Afshar 2011</LINK>). In developing countries case fatality rate is about 50%, whereas in developed countries with intensive care units (ICU) the case fatality rate is less than 20% (<LINK REF="REF-Afshar-2011" TYPE="REFERENCE">Afshar 2011</LINK>).</P>
<P>In developing countries, neonatal tetanus causes over 100,000 infant deaths per year, due largely to poor umbilical hygiene after childbirth. According to the World Health Organization (WHO), Somalia had the highest rate in 1999, with 16.5 neonatal tetanus deaths per 1000 live births (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>). It is noteworthy that vitamin C deficiency has also been particularly common in Somalia (<LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>). Vaccination of mothers would prevent the majority of these cases and the WHO has campaigned to increase the coverage of vaccination in developing countries (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>; <LINK REF="REF-Demicheli-2013" TYPE="REFERENCE">Demicheli 2013</LINK>; <LINK REF="REF-Khan-2013" TYPE="REFERENCE">Khan 2013</LINK>; <LINK REF="REF-WHO-2013" TYPE="REFERENCE">WHO 2013</LINK>).</P>
<P>Although the molecular mechanisms of the tetanus toxin in the initiation of pathogenesis are well known, the later stages of the pathological cascade are inadequately understood. There is evidence indicating that disturbances in autonomic control with sympathetic overactivity (e.g. elevated blood pressure, rapid heart rate) could play a crucial role in the pathophysiology of severe tetanus cases (<LINK REF="REF-Daher-1997" TYPE="REFERENCE">Daher 1997</LINK>; <LINK REF="REF-Wasay-2005" TYPE="REFERENCE">Wasay 2005</LINK>; <LINK REF="REF-CDC-2013" TYPE="REFERENCE">CDC 2013</LINK>). The possible role of catecholamines (stress hormones) in tetanus was supported by data reported by <LINK REF="REF-Thwaites-2006a" TYPE="REFERENCE">Thwaites 2006a</LINK>. The concentrations of epinephrine and norepinephrine were much higher in tetanus patients than in other critically ill patients and, amongst the tetanus patients, the concentrations were higher in those who had more severe forms of tetanus.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-09-12 07:34:07 +0100" MODIFIED_BY="[Empty name]">
<P>Vitamin C was identified in the early 1900s in the search for the substance, the deficiency of which causes scurvy (<LINK REF="REF-Carpenter-1986" TYPE="REFERENCE">Carpenter 1986</LINK>). After the identification there was interest in its effects on diseases unrelated to scurvy, but the role of vitamin C on other diseases is still unsettled.</P>
<P>According to systematic reviews, over two dozen controlled trials have shown that vitamin C shortens the duration of colds (<LINK REF="REF-Hemil_x00e4_-2013" TYPE="REFERENCE">Hemilä 2013</LINK>), five trials found that vitamin C halved the incidence of colds in participants who endured short-term heavy acute physical stress (<LINK REF="REF-Hemil_x00e4_-2013" TYPE="REFERENCE">Hemilä 2013</LINK>), three trials found that vitamin C alleviated exercise-induced bronchoconstriction (<LINK REF="REF-Hemil_x00e4_-2013a" TYPE="REFERENCE">Hemilä 2013a</LINK>), two trials reported therapeutic benefit for pneumonia patients and three reported prophylactic benefit against pneumonia under special circumstances<I>
<B> </B>
</I>(<LINK REF="REF-Hemil_x00e4_-2013b" TYPE="REFERENCE">Hemilä 2013b</LINK>). In randomised trials with critically ill patients, vitamin C alone (<LINK REF="REF-Tanaka-2000" TYPE="REFERENCE">Tanaka 2000</LINK>; <LINK REF="REF-Papoulidis-2011" TYPE="REFERENCE">Papoulidis 2011</LINK>; <LINK REF="REF-Bjorndahl-2012" TYPE="REFERENCE">Bjorndahl 2012</LINK>) or in the combination with vitamin E (<LINK REF="REF-Nathens-2002" TYPE="REFERENCE">Nathens 2002</LINK>) significantly decreased the length of mechanical ventilation or the length of ICU stay or both. Although such findings indicate that the effects of vitamin C are not limited to preventing scurvy, their practical significance is not yet clear.</P>
<P>Two large trials with US male physicians and female health professionals found no benefits of 0.5 g/day of vitamin C (<LINK REF="REF-Cook-2007" TYPE="REFERENCE">Cook 2007</LINK>; <LINK REF="REF-Sesso-2008" TYPE="REFERENCE">Sesso 2008</LINK>), but these trials are not discordant with the possibility that vitamin C administration may influence health on special conditions, such as when a person endures heavy physical activity or suffers from an infection.</P>
<P>An early case report claimed benefit of vitamin C against tetanus in an unvaccinated six-year-old boy in the USA, but the specific role of vitamin C cannot be inferred from the report (<LINK REF="REF-Klenner-1954" TYPE="REFERENCE">Klenner 1954</LINK>).</P>
<P>Usually vitamin C is administered as tablets, but it can also be administered intravenously. A pharmacokinetic study compared oral and intravenous administration and found substantially higher plasma levels when vitamin C was administered by intravenous route compared with oral administration (<LINK REF="REF-Padayatty-2004" TYPE="REFERENCE">Padayatty 2004</LINK>). The highest dose used in the pharmacokinetic study, 100 g of vitamin C intravenously given over a few hours, increased the plasma concentration peak to 15,000 &#956;mol/L, which is over 100 times the plateau level reached by high dose oral administration (<LINK REF="REF-Levine-1996" TYPE="REFERENCE">Levine 1996</LINK>; <LINK REF="REF-Padayatty-2004" TYPE="REFERENCE">Padayatty 2004</LINK>).</P>
<P>Vitamin C is safe in high doses. A dose of approximately 10 mg/day prevents scurvy but, according to the US nutritional recommendations, the 'tolerable upper intake level' is 2 g/day for adults (<LINK REF="REF-IOM-2000" TYPE="REFERENCE">IOM 2000</LINK>). The basis for this upper limit is the appearance of diarrhoea, which is, however, a trivial adverse effect that disappears quickly with a reduction in intake. Several other reviewers have also concluded that vitamin C is safe in doses ranging to several grams per day (<LINK REF="REF-Hathcock-2005" TYPE="REFERENCE">Hathcock 2005</LINK>; <LINK REF="REF-Hemil_x00e4_-2006" TYPE="REFERENCE">Hemilä 2006</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-09-12 07:11:15 +0100" MODIFIED_BY="[Empty name]">
<P>As described above, elevated levels of catecholamines (stress hormones) may play a role in the pathophysiology of tetanus. Vitamin C might influence tetanus, for example, through its effects on catecholamine metabolism. First, vitamin C is involved in the synthesis of norepinephrine and the adrenal glands have the highest concentration of this vitamin in the body (<LINK REF="REF-Diliberto-1991" TYPE="REFERENCE">Diliberto 1991</LINK>; <LINK REF="REF-Rice-2000" TYPE="REFERENCE">Rice 2000</LINK>; <LINK REF="REF-Patak-2004" TYPE="REFERENCE">Patak 2004</LINK>; <LINK REF="REF-Kato-2006" TYPE="REFERENCE">Kato 2006</LINK>). Second, in an animal model vitamin C with vitamin E and &#946;-carotene protected against the cardiotoxic effects of high levels of norepinephrine (<LINK REF="REF-Qin-2001" TYPE="REFERENCE">Qin 2001</LINK>). Third, various infections and purified bacterial toxins deplete vitamin C from the adrenal glands and other tissues (<LINK REF="REF-Hemil_x00e4_-2006" TYPE="REFERENCE">Hemilä 2006</LINK>). Thus, vitamin C might influence conditions where catecholamine metabolism is changed.</P>
<P>A few laboratory studies have shown that vitamin C improved the functions of phagocytes and the proliferation of T-lymphocytes, indicating that it has roles in the immune system (<LINK REF="REF-Hemil_x00e4_-2006" TYPE="REFERENCE">Hemilä 2006</LINK>; <LINK REF="REF-Webb-2007" TYPE="REFERENCE">Webb 2007</LINK>). In dozens of animal studies, vitamin C increased resistance against diverse infections and purified bacterial toxins (<LINK REF="REF-Hemil_x00e4_-2006" TYPE="REFERENCE">Hemilä 2006</LINK>). In particular, <LINK REF="REF-Dey-1966" TYPE="REFERENCE">Dey 1966</LINK> reported that five rats administered twice the minimal lethal dose of tetanus toxin all died, whereas 25 rats administered vitamin C either before or after the toxin all lived (<LINK REF="REF-Hemil_x00e4_-2006" TYPE="REFERENCE">Hemilä 2006</LINK>). Vitamin C also reduced mortality in mice caused by toxins of several <I>Clostridium</I> species (<LINK REF="REF-B_x00fc_ller-Souto-1939" TYPE="REFERENCE">Büller Souto 1939</LINK> [see the data extracted in: <LINK REF="REF-Clemetson-2002" TYPE="REFERENCE">Clemetson 2002</LINK>; <LINK REF="REF-Hemil_x00e4_-2006" TYPE="REFERENCE">Hemilä 2006</LINK>]).</P>
<P>
<LINK REF="REF-Chakrabarti-1955" TYPE="REFERENCE">Chakrabarti 1955</LINK> reported that tetanus patients had lower plasma vitamin C levels than healthy people, and tetanus patients who died had lower levels than those who survived. Furthermore, tetanus patients had elevated levels of dehydroascorbate, which is the oxidized form of vitamin C. Such changes in vitamin C metabolism provide a further rationale to test vitamin C for tetanus patients.</P>
<P>Although vitamin C influences the immune system, it may be important only in particular conditions. For example, it is possible that variation in dietary vitamin C intake is not crucial in the ordinary western population because of their relatively high dietary intake levels, yet vitamin C might be a limiting factor in populations with low intakes. In the extreme, the prevalence of scurvy (vitamin C deficiency) was reported to be up to 44% in refugee camps in Somalia (<LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-09-12 07:01:03 +0100" MODIFIED_BY="Harri Hemilä">
<P>Tetanus is a severe disease afflicting about 1 million people annually and vitamin C is a safe and inexpensive essential nutrient. The possibility that vitamin C may have an action on tetanus is therefore worthy of systematic consideration.</P>
<P>Links to the publications cited in this Background section, for which full text versions are available, can be found at: <A HREF="http://www.mv.helsinki.fi/home/hemila/CT">www.mv.helsinki.fi/home/hemila/CT</A>
</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-01-12 14:35:29 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the effects of vitamin C supplementation for:<BR/>(1) preventing the development of tetanus in vaccinated and unvaccinated individuals; <BR/>(2) treating patients with a diagnosis of tetanus.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-11-13 15:54:24 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-09-10 20:47:11 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-09-10 20:47:11 +0100" MODIFIED_BY="[Empty name]">
<P>Controlled clinical trials, both randomised and non-randomised. The review includes studies with and without placebo control since, firstly, it is unlikely that being aware of taking or not taking vitamin C would influence such a severe disease as tetanus; and secondly, a recent meta-analysis of trials comparing a placebo group with a no-treatment group found no evidence of a substantial placebo effect on binary outcomes, although placebo did have an effect on pain measured as a continuous outcome (<LINK REF="REF-Hrobjartsson-2010" TYPE="REFERENCE">Hrobjartsson 2010</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included studies involving people of any age and sex, either vaccinated or unvaccinated (prevention) or who had a diagnosed condition of tetanus (treatment). In this review we include both neonatal tetanus and tetanus cases occurring after the neonatal period.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-01-06 15:52:59 +0000" MODIFIED_BY="[Empty name]">
<P>Studies in which treatment with vitamin C was the only systematic difference between the treatment arms were eligible for inclusion. We included studies comparing outcomes after the administration of vitamin C (ascorbic acid or its salts or other derivatives; orally or intravenously) with the administration of no or a lower dose of vitamin C. We did not apply restrictions on the dosage and frequency of administration of vitamin C, and we considered treatment trials using a single dose and trials in which vitamin C was administered with other treatments, provided co-interventions did not differ between the treatment arms. We regarded 'prevention trials' as those in which regular vitamin C was administered to people who did not have tetanus and 'treatment trials' as those in which vitamin C was administered after the diagnosis of tetanus.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-01-06 16:03:51 +0000" MODIFIED_BY="[Empty name]">
<P>We applied any definition of tetanus applied by the original study authors.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-01-06 16:03:40 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Prevention trials:</HEADING>
<OL>
<LI>Incidence of tetanus.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment trials:</HEADING>
<OL>
<LI>Mortality;</LI>
<LI>Duration of hospital stay.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-01-06 16:03:51 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Prevention trials:</HEADING>
<OL>
<LI>Mortality;</LI>
<LI>Duration of hospital stay;</LI>
<LI>Severity of symptoms and complications.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment trials:</HEADING>
<OL>
<LI>Severity and occurrence of complications such as fractures and nosocomial infections.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-11-13 15:54:24 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-11-13 15:54:24 +0000" MODIFIED_BY="[Empty name]">
<P>For an outline of the search methods used in second update of this review see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We searched the following databases in May 2013 for this third update:</P>
<UL>
<LI>The Cochrane Wounds Group Specialised Register (searched 22 May 2013);</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2013, Issue 4);</LI>
<LI>Ovid MEDLINE (1946 to May Week 2 2013);</LI>
<LI>Ovid MEDLINE (In-Process &amp; Other Non-Indexed Citations, May 16, 2013);</LI>
<LI>Ovid EMBASE (2011 to 2013 Week 19);</LI>
</UL>
<P>The following strategy was used to search The Cochrane Central Register of Controlled Trials (CENTRAL):<BR/>#1 MeSH descriptor Tetanus explode all trees<BR/>#2 tetanus<BR/>#3 (#1 OR #2)<BR/>#4 MeSH descriptor Ascorbic Acid explode all trees<BR/>#5 ascorb* or "vitamin C"<BR/>#6 (#4 OR #5)<BR/>#7 (#3 AND #6)</P>
<P>The search strategies for Ovid MEDLINE and Ovid EMBASE can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> respectively. No methodological filters were used. No date or language restrictions were applied.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-09-12 07:01:28 +0100" MODIFIED_BY="[Empty name]">
<P>Previously, <LINK REF="REF-Briggs-1984" TYPE="REFERENCE">Briggs 1984</LINK> carried out extensive literature searches and published a bibliography containing over 400 references to papers related to vitamin C and infections, which we checked, as well as the reference lists of two books on potential clinical effects of vitamin C (<LINK REF="REF-Stone-1972" TYPE="REFERENCE">Stone 1972</LINK>; <LINK REF="REF-Levy-2002" TYPE="REFERENCE">Levy 2002</LINK>). We also searched the reference lists of all other pertinent reviews and of the potentially eligible studies identified in our search.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-09-12 07:50:41 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-08-06 17:03:35 +0100" MODIFIED_BY="[Empty name]">
<P>The first review author searched the literature and both review authors independently assessed the titles and abstracts to identify potentially relevant articles. We obtained full versions of all potentially eligible articles, which we scrutinised independently. </P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-09-10 20:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Both review authors independently extracted pertinent data from the articles selected. We recorded the following quality features of the trials on data extraction forms as 'yes', 'no', 'unclear': randomised allocation, allocation concealment, blinding of participants, blinding of investigator, blinding of outcome assessor, blind data analysis and intention-to-treat analysis. We also recorded baseline measurements and percentage dropout during follow up.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-09-12 07:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>We did not calculate any quality scores because "the use of scales for assessing quality or risk of bias is explicitly discouraged in Cochrane reviews" (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We describe the weaknesses and strengths of the included trial explicitly in the '<LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>' section.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-09-06 08:29:36 +0100" MODIFIED_BY="Harri Hemilä">
<P>We entered the case fatality rate data of the identified <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> study to the <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK> computer program and calculated the odds ratio (OR) as an approximation of the risk ratio (RR) (<LINK REF="REF-Rothman-1998" TYPE="REFERENCE">Rothman 1998</LINK>), presenting the results with the 95% confidence intervals (CI). Because one cell in the 2 × 2 table was empty in the comparison of children we used the Peto-method for calculating the OR. We also used the Fisher's exact test of the <LINK REF="REF-R_x002d_Project-2013" TYPE="REFERENCE">R-Project 2013</LINK> package to calculate the exact 95% CI for the OR and the Fisher's exact test P-value for the comparison. We used two-tailed P values in this review.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-06-06 06:55:20 +0100" MODIFIED_BY="[Empty name]">
<P>The patients in the <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial were divided into two wards by vitamin C administration. Although this may cause bias in treatment and observations, it does not affect the unit of analysis (the individual patient), because tetanus is not a contagious disease.</P>
</UNIT_OF_ANALYSIS>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-09-06 08:41:18 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the heterogeneity of comparisons by using I<SUP>2</SUP> (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). This examines the percentage of total variation across studies that is due to heterogeneity rather than chance. A value of I<SUP>2</SUP> greater than about 70% indicates a high level of heterogeneity. We also used the &#967;<SUP>2 </SUP>test to calculate the probability that the observed heterogeneity was caused by chance.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-01-06 16:04:33 +0000" MODIFIED_BY="[Empty name]">
<P>We did not pool the age groups of the <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial, because there was a high level of heterogeneity.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-11-13 16:06:26 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-09-12 07:18:46 +0100" MODIFIED_BY="[Empty name]">
<P>No new eligible trials were identified in the searches carried out for the 2013 update of this review. From the original search we found one eligible controlled trial that provided data pertinent to vitamin C in the treatment of tetanus patients (<LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK>), but we found no trials reporting on the prevention of tetanus with vitamin C. The main features of the Jahan trial are briefly summarised in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>', but described in detail in the following section because its weaknesses and strengths are crucial when considering the validity of it's findings. The <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial was carried out in Bangladesh in the early 1980s. A total of 117 tetanus patients were admitted to the Infectious Disease Hospital in Dhaka and divided into two age groups at recruitment. There were 62 children in the age group 1 to 12 years, and 55 children and adults in the age group 13 to 30 years. The Jahan report is available at <A HREF="http://www.mv.helsinki.fi/home/hemila/CT">www.mv.helsinki.fi/home/hemila/CT</A>
</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-11-13 16:06:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> did not describe the allocation method, but the vitamin C and control arms were of the same size: 31 vitamin C patients compared with 31 control participants in the younger age band; and 27 (vitamin C) compared with 28 (control) in the older participants. Allocation concealment could not be judged from the report. Patients allocated to the vitamin C group received 1 g/day intravenously "in addition to conventional antitetanus therapy which included antitetanus serum, sedatives, antibiotics and muscle relaxant etc." (p 25). Participants allocated to the control arm received conventional antitetanus therapy but the administration of placebo is not mentioned. No baseline data, except for the age ranges, are presented for the two trial arms. There is no description of how tetanus was diagnosed. The authors present results for 117 patients in a table indicating that all recruited patients were included in the analysis. The trialists did not state the duration of intervention or their duration of follow-up, but stated that "patients succumbed to tetanus even three to four weeks after admission" (p 27).</P>
<P>Thus, the <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial had two age groups with treatment and control arms of similar size and administration of vitamin C was the only systematic difference between them. However, the methodological description in the Jahan report is minimal. The role of the methodological shortcomings in the interpretation of the study results are considered in the '<LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>' section.</P>
<P>We were able to contact the first author of the <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial. To our query about the methods of the 1984 trial, we received this reply: "we selected two wards side by side. Patients of one ward were under treatment with vitamin C in addition to conventional treatments. In another ward patients were enrolled as a control group and got only the conventional treatment (without vitamin C). Age groups and the number of patients we tried to match as far as possible. Because we had to take the patients who were inpatients in the hospital we did not use a placebo. We were not able to hide the allocations from the physicians at that stage. Follow up of the patients was until they were discharged as fit persons or died. Diagnosis of the disease was done by a physician specialised in infectious diseases" (Professor Khursheed Jahan, 9 July 2007; personal letter).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-06-14 06:30:20 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Preventing tetanus</HEADING>
<P>We did not identify any trials describing the effects of vitamin C as a prevention for tetanus.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treating tetanus</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Effect on case fatality rate</HEADING>
<P>We identified one controlled trial that examined the effects of 1 g/day vitamin C given intravenously for tetanus patients (<LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK>). At recruitment, the tetanus patients were stratified into two age groups and the results were reported by the age groups. Since one of the 2 × 2 table cells was empty among the younger patients, in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> we present the effect estimates for OR by using the Peto-method.</P>
<P>Age group 1 to 12 years: vitamin C significantly reduced the case fatality rate (0%; 0/31) compared with the control group (74%; 23/31). The Peto-OR for the difference between the vitamin C and control groups was 0.04 (95% CI from 0.02 to 0.12); this is shown as subgroup 1 in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. Because of the empty cell, we also calculated the exact 95% CI for the OR for the young tetanus patients. The exact OR of death was 0.0 (95% CI from 0.0 to 0.06) which is thus slightly narrower than the 95% CI of the Peto-OR (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The Fisher's exact test gives P = 10<SUP>-9</SUP> for the comparison of vitamin C and control arms of the young patients.<BR/>
<BR/>Age group 13 to 30 years: vitamin C significantly reduced the case fatality rate (37%; 10/27) compared with the control group (68%; 19/28). The Peto-OR for the difference between the groups was 0.30 (95% CI from 0.10 to 0.85); this is shown as subgroup 2 in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. The inverse variance RR estimate given by RevMan is RR = 0.55 (95% CI: 0.31 to 0.95; P = 0.03), which is a more practical measure of vitamin C effect than the OR. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Heterogeneity between the subgroups</HEADING>
<P>We found strong evidence of heterogeneity in the effect of vitamin C between the young and old patients with P = 0.01 for the test of heterogeneity over the two age groups. The I<SUP>2</SUP> value of 85% indicates a high level of heterogeneity. The authors of the <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial reported the results of the age groups separately. We did not calculate a pooled vitamin C effect because of the high level of heterogeneity.</P>
<P>Sensitivity analysis based on the rejection of trials with lower methodological quality was not possible because we identified only one trial.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-09-12 07:44:52 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Quality of the evidence</HEADING>
<P>We identified one trial that examined the therapeutic effect of vitamin C on the mortality of people with tetanus (<LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK>). In this 2013 update, no new trials were identified. The <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial reported a highly significant benefit associated with intravenous vitamin C on the case fatality rate of tetanus patients. The methods used in the Jahan trial were, however, unsatisfactory and superficially described. Here we will consider whether potential biases could explain the differences reported in the case fatality rate between the vitamin C and control arms.</P>
<P>
<LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> did not state an explicit case definition for tetanus. Although this is a shortcoming in the report, it does not seem reasonable to assume that tetanus was improperly diagnosed in an infectious diseases hospital in a country that had a high incidence of this disease (currently the incidence is lower). Furthermore, the trial author described in a personal letter that the diagnosis was by a "physician specialised in infectious diseases".</P>
<P>
<B>Selection bias</B> operates when there are systematic differences between comparison groups at baseline. Adequate randomisation with allocation concealment guards against it. No data were presented by <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> to allow us to judge whether the allocation process resulted in balanced allocation between treatment groups for prognostic factors. This trial was not randomised and there is a risk of selection bias (the ward a patient was allocated to determined whether they received vitamin C, and there might have been a systematic difference in the allocation to the wards). However, it is highly unlikely that potential baseline differences could lead to such great difference in mortality between the study arms as reported for the younger patients.</P>
<P>
<B>Performance bias</B> operates when there are systematic differences in the care provided apart from the intervention being evaluated. <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> stated that both vitamin C and control arms received "conventional antitetanus therapy which included antitetanus serum, sedatives, antibiotics and muscle relaxant etc.", so the administration of vitamin C was the only systematic difference between the trial arms. However, the vitamin C and control patients were treated in different wards, which is unsatisfactory because aspects of treatment could be somewhat different between the two wards. Placebo was not used in <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK>, however, a recent meta-analysis showed that, in trials examining various topics, placebo arms did not differ from no-treatment arms if the outcome was binary; e.g. mortality (<LINK REF="REF-Hrobjartsson-2010" TYPE="REFERENCE">Hrobjartsson 2010</LINK>). Thus, the care providers may have been aware of which arm the patients had been enrolled into, but it is highly unlikely that such knowledge would have altered treatment to such an extent that it could explain the difference in mortality between the study arms as reported for the younger patients in <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK>.</P>
<P>
<B>Attrition bias</B> operates when there are large numbers of people who withdraw from the study or when the rates of withdrawal are different between treatment arms. Attrition bias is unlikely in <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK>, since all patients allocated were followed up and analysed. Furthermore, in a personal letter, the trial author confirmed that all patients were followed up "until they were discharged as fit persons or died".</P>
<P>
<B>Detection bias</B> operates when there are systematic differences in the ways outcomes were assessed between treatment groups and is more likely to occur when there is no blinded outcome assessment and when the outcome is subjective. It is unlikely, however, that detection bias is operating in <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> since the outcome was mortality which is not a subjective outcome. There is minimal possibility of bias in detecting mortality in a hospital.</P>
<P>Consequently, although the methods of the <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial are poorly described and the trial was poorly conducted, the biases discussed above cannot explain the reported findings. There seems to be no basis to assume attrition bias or detection bias in the trial. Possibly there has been selection bias and performance bias to some degree, but this cannot explain the reported difference in outcomes among the younger participants. <LINK REF="REF-Glasziou-2007" TYPE="REFERENCE">Glasziou 2007</LINK> argued that rate ratios beyond 10 are highly likely to reflect real treatment effects, even if confounding factors may contribute to the size of the observed effect. In the younger patients of the Jahan trial, the entire 95% CI and not just the point estimate is beyond the ratio of 10. In the older patients of the Jahan trial, the upper limit of the 95% CI is close to the control group level, and therefore the results are not robust to the possibility of selection and performance biases. Nevertheless, the findings in the older patients are consistent with the findings in the younger patients.</P>
<P>Finally, the existence of a single positive study might be explained by <B>publication bias</B>, meaning that researchers tend to report studies with 'positive' results but not those with 'negative' results. With this reasoning, it is possible that <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> was published just because vitamin C appeared beneficial (but simply by chance), whereas several trials might remain unpublished because of their negative results. Publication bias may explain findings that are close to statistical significance, but it is not a reasonable explanation for highly statistically significant findings such as those of the younger patients in the <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial. Furthermore, it would seem incomprehensible that publication bias would generate the highly significant heterogeneity over the age groups. Therefore we do not consider that publication bias is relevant in this case.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Applicability of the evidence</HEADING>
<P>The <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial is methodologically unsatisfactory and caution is required in the interpretation of the results. There are no other trials with humans giving independent direct support to the findings. Nevertheless, in western countries tetanus patients are treated in ICUs, and four randomised trials with critically ill patients found that vitamin C alone or with vitamin E reduced the duration of mechanical ventilation or the length of ICU stay or both (<LINK REF="REF-Tanaka-2000" TYPE="REFERENCE">Tanaka 2000</LINK>; <LINK REF="REF-Nathens-2002" TYPE="REFERENCE">Nathens 2002</LINK>; <LINK REF="REF-Papoulidis-2011" TYPE="REFERENCE">Papoulidis 2011</LINK>; <LINK REF="REF-Bjorndahl-2012" TYPE="REFERENCE">Bjorndahl 2012</LINK>).</P>
<P>In the <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial, vitamin C was used over and above treatments that are still used for treating tetanus patients. In this respect, the trial is not outdated.</P>
<P>When considering extrapolation of the findings of vitamin C trials, one issue of particular importance is the level of dietary vitamin C intake. A different outcome between the vitamin C and control arms may result from a particularly low dietary intake in the control arm ('marginal vitamin C deficiency') or from the high dose supplementation in the vitamin C arm. In the former case, a small dosage of supplement may produce a similar effect, whereas in the latter case the high dose is necessary. As reference levels: scurvy may be caused by vitamin C intake of less than 10 mg/day, whereas the mean vitamin C intake, for example, in the USA is about 100 mg/day (<LINK REF="REF-IOM-2000" TYPE="REFERENCE">IOM 2000</LINK>).</P>
<P>If the biological basis for the results in <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> was the treatment of marginal deficiency, this would not provide an explanation for the significant heterogeneity between the age groups, as the dose is so high that it would cure marginal deficiency in both age groups. Thus, it is possible that the high dose, 1 g/day, was essential for the results. The benefit of vitamin C was significantly greater for the younger patients (1 to 12 years), who weigh on average less than the older patients (13 to 30 years). Thus the heterogeneity might have resulted from dose dependency because the dose per weight was higher in the younger patients. However, there are other differences between the younger and older patients, and some of them might explain the heterogeneity as well.</P>
<P>In the <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> trial, vitamin C was administered intravenously which increases plasma level substantially more than oral administration (<LINK REF="REF-Padayatty-2004" TYPE="REFERENCE">Padayatty 2004</LINK>). Therefore, the same dose of vitamin C as tablets might not have similar effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety of vitamin C</HEADING>
<P>In the <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> report, no adverse effects related to the intravenous 1 g/day vitamin C administration were mentioned.</P>
<P>Two large-scale trials with 8171 female health professionals and 14,641 male physicians found no adverse effects of 0.5 g/day of vitamin C when administered for 8 to 9 years indicating long term safety of such a dosage level (<LINK REF="REF-Cook-2007" TYPE="REFERENCE">Cook 2007</LINK>; <LINK REF="REF-Sesso-2008" TYPE="REFERENCE">Sesso 2008</LINK>).</P>
<P>There is also evidence that high dose vitamin C is usually safe when administered intravenously. A matched case control study of cancer patients found that 10 g/day vitamin C by intravenous infusion for 10 days and orally thereafter was associated with a longer survival time which indicates the absence of harmful effects with such a dosage (<LINK REF="REF-Cameron-1976" TYPE="REFERENCE">Cameron 1976</LINK>). Large doses of vitamin C have been administered intravenously for numerous patients without adverse effects (<LINK REF="REF-Padayatty-2006" TYPE="REFERENCE">Padayatty 2006</LINK>; <LINK REF="REF-Padayatty-2010" TYPE="REFERENCE">Padayatty 2010</LINK>). In a pharmacokinetic study, no adverse effects were reported with the administration of up to 100 g of vitamin C intravenously to healthy people (<LINK REF="REF-Padayatty-2004" TYPE="REFERENCE">Padayatty 2004</LINK>). A case report described the use of intravenous vitamin C doses at levels up to 28 g/day for a six-year-old boy with tetanus (<LINK REF="REF-Klenner-1954" TYPE="REFERENCE">Klenner 1954</LINK>).</P>
<P>
<LINK REF="REF-Cathcart-1981" TYPE="REFERENCE">Cathcart 1981</LINK> stated that patients with severe infections can take over 30 g/day of vitamin C orally without suffering from diarrhoea, whereas healthy people can take only 4 to 10 g/day. This difference in tolerable doses may be caused by the changes in vitamin C metabolism because of severe infections (<LINK REF="REF-Chakrabarti-1955" TYPE="REFERENCE">Chakrabarti 1955</LINK>; <LINK REF="REF-Hemil_x00e4_-2006" TYPE="REFERENCE">Hemilä 2006</LINK>). Thus, it is possible that the range of safe doses extends to higher levels in people who have severe infections compared with healthy people.</P>
<P>There are few reports of severe harm caused by high-dose vitamin C administration. Furthermore, the death of a 68-year-old African American man was not attributed to the intravenous injection of 80 grams of vitamin C on two consecutive days <I>per se</I>, but to his coincident glucose-6-phosphate dehydrogenase deficiency (G6PD) (<LINK REF="REF-Campbell-1975" TYPE="REFERENCE">Campbell 1975</LINK>). Such unfortunate events do not have public health importance, although they discourage use of large vitamin C doses to G6PD patients.</P>
<P>Consequently, there seems to be no concern about the safety of the intravenous dosage level, 1 g/day, used in <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK>.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-09-05 14:43:15 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-09-05 14:43:15 +0100" MODIFIED_BY="Harri Hemilä">
<P>A single poor quality and poorly reported controlled trial found that 1 g/day intravenous vitamin C significantly reduced tetanus case fatality rate. Potential biases do not easily explain the differences between the vitamin C and control groups, but the shortcomings of this trial mean that routine vitamin C use cannot be recommended on the basis of this trial alone. There were no evaluations of vitamin C as a prevention for tetanus.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-06-13 08:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment trials: the particularly dramatic effect reported for children in <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK> implies that more research is needed into the effect of vitamin C on mortality of tetanus patients. Vitamin C should be studied as an addition to conventional therapy.</P>
<P>Prevention trials: because of vaccination, tetanus is nearly non-existent in children and middle-aged people in the developed world. Although vaccination should be a priority in developing countries, the prophylactic effects of vitamin C supplementation might be investigated in populations with a high incidence of tetanus and low dietary vitamin C intake levels, which coexist, for example, in Somalia (<LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>; <LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-01-20 17:52:04 +0000" MODIFIED_BY="[Empty name]">
<P>We are grateful to Sally Bell-Syer, Duncan Chambers, Nicky Cullum, Ruth Foxlee, Andrew Jull, Andrea Nelson, Louise Thwaites, Gill Worthy and Amy Zelmer for their comments on improving the draft review, and for Margaret Carver for copy editing the review. Thanks to Helena Mullineaux who copy edited the updated review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-10-30 11:04:55 +0000" MODIFIED_BY="Harri Hemilä">
<P>
<B> </B>No conflicts of interest for Harri Hemilä and Teija Koivula.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-06-13 08:03:23 +0100" MODIFIED_BY="[Empty name]">
<P>HH wrote the draft of the protocol and TK commented on the draft. HH carried out the literature searches. Both authors assessed the search results to identify potentially relevant articles and extracted data from the articles selected. HH carried out the statistical analysis and wrote the draft of the review and TK commented on the draft. HH updated the review and TK commented the updated version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-09-06 08:36:24 +0100" MODIFIED_BY="[Empty name]">
<P>In the previous versions of the review, the Mantel-Haenszel method (M-H) was used to calculate the RR as an estimate of the vitamin C effect. However, since one of the cells in the 2 × 2 table for the younger tetanus patients was empty, the M-H method gives substantially conservative estimates, which means much too wide 95% CI. Therefore the Peto-method was used in the 2013 update for calculating the OR as an approximation of the RR. For the young tetanus patients (1 to 12 yr), the 95% CI limits of the Peto-OR are much closer to the exact OR limits, and the P-value given by the Peto-method to the young tetanus patients (P = 9.9 x 10<SUP>-10</SUP>, Z = 6.0) is close to the Fisher's exact test (P = 2.6 x 10<SUP>-10</SUP>). This change does not influence the conclusions but makes the presentation in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> more appropriate.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2013-09-12 07:05:18 +0100" MODIFIED_BY="[Empty name]">
<P>Links to full text papers cited in this review are available at: <A HREF="http://www.mv.helsinki.fi/home/hemila/CT">www.mv.helsinki.fi/home/hemila/CT</A>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-11-13 16:14:44 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-06-12 15:03:36 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-06-06 08:14:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Jahan-1984" MODIFIED="2013-06-06 08:14:48 +0100" MODIFIED_BY="[Empty name]" NAME="Jahan 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-06-06 08:14:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jahan K, Ahmad K, Ali MA</AU>
<TI>Effect of ascorbic acid in the treatment of tetanus</TI>
<SO>Bangladesh Medical Research Council Bulletin</SO>
<YR>1984</YR>
<VL>10</VL>
<NO>1</NO>
<PG>24-8</PG>
<IDENTIFIERS MODIFIED="2013-06-06 08:14:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-06 08:14:48 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.mv.helsinki.fi/home/hemila/CT/Jahan1984.pdf"/>
<IDENTIFIER MODIFIED="2013-06-04 11:57:41 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6466264"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-13 16:13:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jahan K</AU>
<TI>Letter from Professor Khursheed Jahan</TI>
<SO>9 July 2007</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-06-12 15:03:36 +0100" MODIFIED_BY="[Empty name]"/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-11-13 16:14:44 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-11-13 16:14:44 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Afshar-2011" MODIFIED="2013-06-16 19:59:58 +0100" MODIFIED_BY="Harri Hemilä" NAME="Afshar 2011" TYPE="JOURNAL_ARTICLE">
<AU>Afshar M, Raju M, Ansell D, Bleck TP</AU>
<TI>Tetanus-a health threat after natural disasters in developing countries</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2011</YR>
<VL>154</VL>
<NO>5</NO>
<PG>329-35</PG>
<IDENTIFIERS MODIFIED="2013-06-12 14:40:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-12 14:40:57 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.7326/0003-4819-154-5-201103010-00007"/>
<IDENTIFIER MODIFIED="2013-06-12 14:40:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21357910"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ataro-2011" MODIFIED="2013-09-10 19:32:35 +0100" MODIFIED_BY="Harri Hemilä" NAME="Ataro 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ataro P, Mushatt D, Ahsan S</AU>
<TI>Tetanus: a review</TI>
<SO>Southern Medical Journal</SO>
<YR>2011</YR>
<VL>104</VL>
<NO>8</NO>
<PG>613-7</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:32:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:32:35 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1097/SMJ.0b013e318224006d"/>
<IDENTIFIER MODIFIED="2013-09-10 19:32:18 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21886075"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bjorndahl-2012" MODIFIED="2013-09-10 19:15:59 +0100" MODIFIED_BY="[Empty name]" NAME="Bjorndahl 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bjordahl PM, Helmer SD, Gosnell DJ, Wemmer GE, O'Hara WW, Milfeld DJ</AU>
<TI>Perioperative supplementation with ascorbic acid does not prevent atrial fibrillation in coronary artery bypass graft patients</TI>
<SO>American Journal of Surgery</SO>
<YR>2012</YR>
<VL>204</VL>
<NO>6</NO>
<PG>862-7</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:15:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:15:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.amjsurg.2012.03.012"/>
<IDENTIFIER MODIFIED="2013-09-10 19:15:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23022248"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Briggs-1984" MODIFIED="2011-08-24 10:26:03 +0100" MODIFIED_BY="[Empty name]" NAME="Briggs 1984" TYPE="BOOK_SECTION">
<AU>Briggs M</AU>
<TI>Vitamin C and infectious disease: a review of the literature and the results of a randomized, double-blind, prospective study over 8 years</TI>
<SO>Recent Vitamin Research</SO>
<YR>1984</YR>
<PG>39-82</PG>
<ED>Briggs MH</ED>
<PB>CRC Press</PB>
<CY>Boca Raton, FL</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-B_x00fc_ller-Souto-1939" MODIFIED="2013-09-06 08:35:01 +0100" MODIFIED_BY="[Empty name]" NAME="Büller Souto 1939" TYPE="JOURNAL_ARTICLE">
<AU>Büller Souto A, Lima C</AU>
<TI>Effect of vitamin C on Bacillus perfringensis toxin (see data extracted and analysed in Clemetson 2002 and in Hemilä 2006:115)</TI>
<TO>Action de la vitamine C sur la toxine du Bacillus perfringens</TO>
<SO>Memorias do Instituto Butantan</SO>
<YR>1939</YR>
<VL>12</VL>
<PG>265-95 [in Portuguese]; 297-311 [in French; same data]</PG>
<IDENTIFIERS MODIFIED="2013-06-06 08:15:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-06 08:15:12 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.mv.helsinki.fi/home/hemila/CT/Buller1939.pdf"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cameron-1976" MODIFIED="2013-09-10 19:44:22 +0100" MODIFIED_BY="Harri Hemilä" NAME="Cameron 1976" TYPE="JOURNAL_ARTICLE">
<AU>Cameron E, Pauling L</AU>
<TI>Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer</TI>
<SO>Proceedings of the National Academy of Sciences of the USA</SO>
<YR>1976</YR>
<VL>73</VL>
<NO>10</NO>
<PG>3685-9</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:44:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:44:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1073/pnas.73.10.3685"/>
<IDENTIFIER MODIFIED="2013-09-10 19:43:29 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1068480"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Campbell-1975" MODIFIED="2013-09-10 19:34:56 +0100" MODIFIED_BY="Harri Hemilä" NAME="Campbell 1975" TYPE="JOURNAL_ARTICLE">
<AU>Campbell GD, Steinberg MH, Bower JD</AU>
<TI>Ascorbic acid-induced hemolysis in G-6-PD deficiency</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1975</YR>
<VL>82</VL>
<NO>6</NO>
<PG>810</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:34:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-06 08:15:22 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.mv.helsinki.fi/home/hemila/CC/Campbell1975.pdf"/>
<IDENTIFIER MODIFIED="2013-09-10 19:34:56 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1138591"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1986" MODIFIED="2013-09-10 19:30:37 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1986" TYPE="BOOK">
<AU>Carpenter KJ</AU>
<SO>The History of Scurvy and Vitamin C</SO>
<YR>1986</YR>
<PB>Cambridge University Press</PB>
<CY>Cambridge</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cathcart-1981" MODIFIED="2013-09-10 19:36:04 +0100" MODIFIED_BY="Harri Hemilä" NAME="Cathcart 1981" TYPE="JOURNAL_ARTICLE">
<AU>Cathcart RF</AU>
<TI>Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy</TI>
<SO>Medical Hypotheses</SO>
<YR>1981</YR>
<VL>7</VL>
<NO>11</NO>
<PG>1359-76</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:36:04 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:36:04 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/0306-9877(81)90126-2"/>
<IDENTIFIER MODIFIED="2013-09-10 19:35:52 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7321921"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CDC-2013" MODIFIED="2013-06-11 06:31:16 +0100" MODIFIED_BY="[Empty name]" NAME="CDC 2013" TYPE="OTHER">
<AU>CDC (Centers for Disease Control and Prevention)</AU>
<TI>Tetanus</TI>
<SO>http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf</SO>
<YR>2013</YR>
<IDENTIFIERS MODIFIED="2013-06-04 14:15:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chakrabarti-1955" MODIFIED="2013-09-10 19:36:47 +0100" MODIFIED_BY="Harri Hemilä" NAME="Chakrabarti 1955" TYPE="JOURNAL_ARTICLE">
<AU>Chakrabarti B, Banerjee S</AU>
<TI>Dehydroascorbic acid level in blood of patients suffering from various infectious diseases</TI>
<SO>Proceedings of the Society for Experimental Biology and Medicine</SO>
<YR>1955</YR>
<VL>88</VL>
<NO>4</NO>
<PG>581-3</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:36:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-19 17:02:38 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.mv.helsinki.fi/home/hemila/CT/Chakrabarti1955.pdf"/>
<IDENTIFIER MODIFIED="2013-09-10 19:36:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14371706"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clemetson-2002" MODIFIED="2013-09-10 19:38:53 +0100" MODIFIED_BY="[Empty name]" NAME="Clemetson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Clemetson CA</AU>
<TI>Barlow's disease</TI>
<SO>Medical Hypotheses</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>1</NO>
<PG>52-6</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:38:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:38:53 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0306-9877(02)00114-7"/>
<IDENTIFIER MODIFIED="2013-09-10 19:37:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12160680"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cook-2007" MODIFIED="2013-09-10 19:46:34 +0100" MODIFIED_BY="[Empty name]" NAME="Cook 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cook NR, Albert CM, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al</AU>
<TI>A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2007</YR>
<VL>167</VL>
<NO>15</NO>
<PG>1610-8</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:46:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:46:27 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1001/archinte.167.15.1610"/>
<IDENTIFIER MODIFIED="2013-09-10 19:46:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17698683"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Daher-1997" MODIFIED="2013-09-10 19:40:09 +0100" MODIFIED_BY="Harri Hemilä" NAME="Daher 1997" TYPE="JOURNAL_ARTICLE">
<AU>Daher EF, Abdulkader RC, Motti E, Marcondes M, Sabbaga E, Burdmann EA</AU>
<TI>Prospective study of tetanus-induced acute renal dysfunction: role of adrenergic overactivity</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>57</VL>
<NO>5</NO>
<PG>610-4</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:40:09 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:40:09 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9392604"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Demicheli-2013" MODIFIED="2013-09-10 20:37:08 +0100" MODIFIED_BY="[Empty name]" NAME="Demicheli 2013" TYPE="COCHRANE_REVIEW">
<AU>Demicheli V, Barale A, Rivetti A</AU>
<TI>Vaccines for women to prevent neonatal tetanus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2013-09-10 20:37:08 +0100" MODIFIED_BY="Harri Hemilä">
<IDENTIFIER MODIFIED="2013-09-10 19:39:23 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002959.pub3"/>
<IDENTIFIER MODIFIED="2013-09-10 20:37:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23728640"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dey-1966" MODIFIED="2013-09-10 19:48:05 +0100" MODIFIED_BY="Harri Hemilä" NAME="Dey 1966" TYPE="JOURNAL_ARTICLE">
<AU>Dey PK</AU>
<TI>Efficacy of vitamin C in counteracting tetanus toxin toxicity</TI>
<SO>Naturwissenschaften</SO>
<YR>1966</YR>
<VL>53</VL>
<NO>12</NO>
<PG>310</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:48:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:48:05 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="5986216"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Diliberto-1991" MODIFIED="2013-09-10 19:48:48 +0100" MODIFIED_BY="[Empty name]" NAME="Diliberto 1991" TYPE="JOURNAL_ARTICLE">
<AU>Diliberto EJ Jr, Daniels AJ, Viveros OH</AU>
<TI>Multicompartmental secretion of ascorbate and its dual role in dopamine beta-hydroxylation</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1991</YR>
<VL>54</VL>
<NO>Suppl 6</NO>
<PG>1163S-72S</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:48:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:48:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1962565"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gergen-1995" MODIFIED="2013-09-10 19:50:03 +0100" MODIFIED_BY="Harri Hemilä" NAME="Gergen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G</AU>
<TI>A population-based serologic survey of immunity to tetanus in the United States</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>332</VL>
<NO>12</NO>
<PG>761-6</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:50:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:50:03 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1056/NEJM199503233321201"/>
<IDENTIFIER MODIFIED="2013-09-10 19:49:31 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7862178"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gibson-2009" MODIFIED="2013-09-10 19:51:15 +0100" MODIFIED_BY="[Empty name]" NAME="Gibson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Gibson K, Bonaventure Uwineza J, Kiviri W, Parlow J</AU>
<TI>Tetanus in developing countries: a case series and review</TI>
<SO>Canadian Journal of Anesthesia</SO>
<YR>2009</YR>
<VL>56</VL>
<NO>4</NO>
<PG>307-15</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:51:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:51:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s12630-009-9058-1"/>
<IDENTIFIER MODIFIED="2013-09-10 19:51:15 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19296192"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glasziou-2007" MODIFIED="2013-09-10 19:52:57 +0100" MODIFIED_BY="Harri Hemilä" NAME="Glasziou 2007" TYPE="JOURNAL_ARTICLE">
<AU>Glasziou P, Chalmers I, Rawlins M, McCulloch P</AU>
<TI>When are randomised trials unnecessary? Picking signal from noise</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>334</VL>
<NO>7589</NO>
<PG>349-51</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:52:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:52:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmj.39070.527986.68"/>
<IDENTIFIER MODIFIED="2013-09-10 19:52:57 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17303884"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hathcock-2005" MODIFIED="2013-09-10 19:53:47 +0100" MODIFIED_BY="Harri Hemilä" NAME="Hathcock 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hathcock JN, Azzi A, Blumberg J, Bray T, Dickinson A, Frei B, et al</AU>
<TI>Vitamins E and C are safe across a broad range of intakes</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>81</VL>
<NO>4</NO>
<PG>736-45</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:53:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:53:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15817846"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2006" MODIFIED="2013-07-19 17:03:50 +0100" MODIFIED_BY="[Empty name]" NAME="Hemilä 2006" TYPE="OTHER">
<AU>Hemilä H</AU>
<TI>Do vitamins C and E affect respiratory infections?</TI>
<SO>[Dissertation] University of Helsinki, Helsinki, Finland</SO>
<YR>2006</YR>
<PG>5-9,62-63,112,115</PG>
<IDENTIFIERS MODIFIED="2013-07-19 17:03:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2013" MODIFIED="2013-09-10 20:36:05 +0100" MODIFIED_BY="[Empty name]" NAME="Hemilä 2013" TYPE="COCHRANE_REVIEW">
<AU>Hemilä H, Chalker EB</AU>
<TI>Vitamin C for preventing and treating the common cold</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-09-10 20:36:05 +0100" MODIFIED_BY="Harri Hemilä">
<IDENTIFIER MODIFIED="2013-06-04 11:52:32 +0100" MODIFIED_BY="Harri Hemilä" TYPE="DOI" VALUE="10.1002/14651858.CD000980.pub4"/>
<IDENTIFIER MODIFIED="2013-09-10 20:36:05 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23440782"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2013a" MODIFIED="2013-09-10 19:54:24 +0100" MODIFIED_BY="[Empty name]" NAME="Hemilä 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Hemilä H</AU>
<TI>Vitamin C may alleviate exercise-induced bronchoconstriction: a meta-analysis</TI>
<SO>BMJ Open</SO>
<YR>2013</YR>
<VL>3</VL>
<NO>6</NO>
<PG>e002416</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:54:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-19 17:04:28 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmjopen-2012-002416"/>
<IDENTIFIER MODIFIED="2013-09-10 19:54:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23794586"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2013b" MODIFIED="2013-09-10 20:35:03 +0100" MODIFIED_BY="[Empty name]" NAME="Hemilä 2013b" TYPE="COCHRANE_REVIEW">
<AU>Hemilä H, Louhiala P</AU>
<TI>Vitamin C for preventing and treating pneumonia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2013-09-10 20:35:00 +0100" MODIFIED_BY="Harri Hemilä">
<IDENTIFIER MODIFIED="2013-09-10 20:34:24 +0100" MODIFIED_BY="Harri Hemilä" TYPE="DOI" VALUE="10.1002/14651858.CD005532.pub3"/>
<IDENTIFIER MODIFIED="2013-09-10 20:35:00 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23925826"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-09-10 19:55:33 +0100" MODIFIED_BY="Harri Hemilä" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:55:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:55:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmj.327.7414.557"/>
<IDENTIFIER MODIFIED="2013-09-10 19:55:26 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-11-13 16:14:44 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<VL>section 8.3.3</VL>
<EN>Version 5.1 [updated March 2011]</EN>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS MODIFIED="2013-07-19 17:04:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hrobjartsson-2010" MODIFIED="2013-09-10 20:36:24 +0100" MODIFIED_BY="[Empty name]" NAME="Hrobjartsson 2010" TYPE="COCHRANE_REVIEW">
<AU>Hrobjartsson A, Gotzsche PC</AU>
<TI>Placebo interventions for all clinical conditions</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-09-10 20:36:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-08-24 10:58:31 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003974.pub3"/>
<IDENTIFIER MODIFIED="2013-09-10 20:36:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20091554"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-IOM-2000" NAME="IOM 2000" TYPE="BOOK_SECTION">
<AU>IOM (Institute of Medicine)</AU>
<TI>Vitamin C</TI>
<SO>Dietary reference intakes for vitamin C, vitamin E, selenium and carotenoids</SO>
<YR>2000</YR>
<PG>95-185</PG>
<PB>National Academy Press</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kato-2006" MODIFIED="2013-09-10 19:57:26 +0100" MODIFIED_BY="[Empty name]" NAME="Kato 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kato K, Fukuma N, Kimura-Kato Y, Aisu N, Tuchida T, Mabuchi K</AU>
<TI>Improvement of sympathetic response to exercise by oral administration of ascorbic acid in patients after myocardial infarction</TI>
<SO>International Journal of Cardiology</SO>
<YR>2006</YR>
<VL>111</VL>
<NO>2</NO>
<PG>240-6</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:57:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:57:26 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.ijcard.2005.07.020"/>
<IDENTIFIER MODIFIED="2013-09-10 19:57:03 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16246442"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khan-2013" MODIFIED="2013-09-10 19:58:07 +0100" MODIFIED_BY="[Empty name]" NAME="Khan 2013" TYPE="JOURNAL_ARTICLE">
<AU>Khan AA, Zahidie A, Rabbani F</AU>
<TI>Interventions to reduce neonatal mortality from neonatal tetanus in low and middle income countries--a systematic review</TI>
<SO>BMC Public Health</SO>
<YR>2013</YR>
<VL>13</VL>
<PG>322</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:58:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-19 17:04:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1471-2458-13-322"/>
<IDENTIFIER MODIFIED="2013-09-10 19:58:07 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23570611"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Klenner-1954" MODIFIED="2013-06-06 08:16:48 +0100" MODIFIED_BY="[Empty name]" NAME="Klenner 1954" TYPE="JOURNAL_ARTICLE">
<AU>Klenner FR</AU>
<TI>Recent discoveries in the treatment of lockjaw with vitamin C and tolserol</TI>
<SO>Tri-State Medical Journal</SO>
<YR>1954</YR>
<VL>2</VL>
<NO>July</NO>
<PG>7-11</PG>
<IDENTIFIERS MODIFIED="2013-06-06 08:16:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-06 08:16:48 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.mv.helsinki.fi/home/hemila/CT/Klenner1954.pdf"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levine-1996" MODIFIED="2013-09-10 20:00:14 +0100" MODIFIED_BY="Harri Hemilä" NAME="Levine 1996" TYPE="JOURNAL_ARTICLE">
<AU>Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, et al</AU>
<TI>Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance</TI>
<SO>Proceedings of the National Academy of Sciences of the USA</SO>
<YR>1996</YR>
<VL>93</VL>
<NO>8</NO>
<PG>3704-9</PG>
<IDENTIFIERS MODIFIED="2013-09-10 20:00:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 20:00:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1073/pnas.93.8.3704"/>
<IDENTIFIER MODIFIED="2013-09-10 20:00:14 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8623000"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levy-2002" MODIFIED="2011-08-24 10:59:06 +0100" MODIFIED_BY="[Empty name]" NAME="Levy 2002" TYPE="BOOK">
<AU>Levy TE</AU>
<SO>Vitamin C, Infectious Diseases, and Toxins</SO>
<YR>2002</YR>
<PB>Xlibris</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nathens-2002" MODIFIED="2013-07-19 17:05:19 +0100" MODIFIED_BY="[Empty name]" NAME="Nathens 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, et al</AU>
<TI>Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients</TI>
<SO>Annals of Surgery</SO>
<YR>2002</YR>
<VL>236</VL>
<NO>6</NO>
<PG>814-22</PG>
<IDENTIFIERS MODIFIED="2013-07-19 17:05:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422648/"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Padayatty-2004" MODIFIED="2013-09-10 20:01:46 +0100" MODIFIED_BY="Harri Hemilä" NAME="Padayatty 2004" TYPE="JOURNAL_ARTICLE">
<AU>Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al</AU>
<TI>Vitamin C pharmacokinetics: implications for oral and intravenous use</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<NO>7</NO>
<PG>533-7</PG>
<IDENTIFIERS MODIFIED="2013-09-10 20:01:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 20:01:46 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.7326/0003-4819-140-7-200404060-00010"/>
<IDENTIFIER MODIFIED="2013-09-10 20:01:38 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15068981"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Padayatty-2006" MODIFIED="2013-09-10 20:03:00 +0100" MODIFIED_BY="Harri Hemilä" NAME="Padayatty 2006" TYPE="JOURNAL_ARTICLE">
<AU>Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M</AU>
<TI>Intravenously administered vitamin C as cancer therapy: three cases</TI>
<SO>CMAJ</SO>
<YR>2006</YR>
<VL>174</VL>
<NO>7</NO>
<PG>937-42</PG>
<IDENTIFIERS MODIFIED="2013-09-10 20:03:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 20:03:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1503/cmaj.050346"/>
<IDENTIFIER MODIFIED="2013-09-10 20:02:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16567755"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Padayatty-2010" MODIFIED="2013-09-10 20:03:58 +0100" MODIFIED_BY="[Empty name]" NAME="Padayatty 2010" TYPE="JOURNAL_ARTICLE">
<AU>Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M</AU>
<TI>Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects</TI>
<SO>PLoS One</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>7</NO>
<PG>e11414</PG>
<IDENTIFIERS MODIFIED="2013-09-10 20:03:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1371/journal.pone.0011414"/>
<IDENTIFIER MODIFIED="2013-09-10 20:03:58 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20628650"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Papoulidis-2011" MODIFIED="2013-09-10 21:06:00 +0100" MODIFIED_BY="[Empty name]" NAME="Papoulidis 2011" TYPE="JOURNAL_ARTICLE">
<AU>Papoulidis P, Ananiadou O, Chalvatzoulis E, Ampatzidou F, Koutsogiannidis C, Karaiskos T, et al</AU>
<TI>The role of ascorbic acid in the prevention of atrial fibrillation after elective on-pump myocardial revascularization surgery: a single-center experience--a pilot study</TI>
<SO>Interactive Cardiovascular and Thoracic Surgery</SO>
<YR>2011</YR>
<VL>12</VL>
<NO>2</NO>
<PG>121-4</PG>
<IDENTIFIERS MODIFIED="2013-09-10 21:06:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 21:06:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1510/icvts.2010.240473"/>
<IDENTIFIER MODIFIED="2013-09-10 21:05:45 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21098510"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Patak-2004" MODIFIED="2013-09-10 20:05:11 +0100" MODIFIED_BY="Harri Hemilä" NAME="Patak 2004" TYPE="JOURNAL_ARTICLE">
<AU>Patak P, Willenberg HS, Bornstein SR</AU>
<TI>Vitamin C is an important cofactor for both adrenal cortex and adrenal medulla</TI>
<SO>Endocrine Research</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>4</NO>
<PG>871-5</PG>
<IDENTIFIERS MODIFIED="2013-09-10 20:05:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 20:05:11 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1081/ERC-200044126"/>
<IDENTIFIER MODIFIED="2013-09-10 20:05:00 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15666839"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Qin-2001" MODIFIED="2013-07-19 17:05:41 +0100" MODIFIED_BY="[Empty name]" NAME="Qin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Qin F, Rounds NK, Mao W, Kawai K, Liang CS</AU>
<TI>Antioxidant vitamins prevent cardiomyocyte apoptosis produced by norepinephrine infusion in ferrets</TI>
<SO>Cardiovascular Research</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>4</NO>
<PG>736-48</PG>
<IDENTIFIERS MODIFIED="2013-07-19 17:05:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-R_x002d_Project-2013" MODIFIED="2013-07-19 17:08:57 +0100" MODIFIED_BY="Harri Hemilä" NAME="R-Project 2013" TYPE="COMPUTER_PROGRAM">
<TI>The R Project for Statistical Computing</TI>
<YR>2013</YR>
<PB>http://www.r-project.org/</PB>
<IDENTIFIERS MODIFIED="2013-06-09 20:06:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Reddy-2010" MODIFIED="2013-06-11 06:43:02 +0100" MODIFIED_BY="[Empty name]" NAME="Reddy 2010" TYPE="BOOK_SECTION">
<AU>Reddy P, Bleck TP</AU>
<TI>Clostridium tetani (tetanus)</TI>
<SO>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>3091-6</PG>
<EN>7th</EN>
<ED>Mandell GL, Bennett JE, Dolin R</ED>
<PB>Elsevier Churchill Livingstone</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-06-04 12:57:32 +0100" MODIFIED_BY="Harri Hemilä" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<MD>http://ims.cochrane.org/revman</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rice-2000" MODIFIED="2013-09-10 20:07:22 +0100" MODIFIED_BY="Harri Hemilä" NAME="Rice 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rice ME</AU>
<TI>Ascorbate regulation and its neuroprotective role in the brain</TI>
<SO>Trends in Neurological Sciences</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>5</NO>
<PG>209-16</PG>
<IDENTIFIERS MODIFIED="2013-09-10 20:07:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 20:07:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0166-2236(99)01543-X"/>
<IDENTIFIER MODIFIED="2013-09-10 20:07:22 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10782126"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rothman-1998" NAME="Rothman 1998" TYPE="BOOK_SECTION">
<AU>Rothman KJ, Greenland S</AU>
<TI>Small sample statistics for pure count data</TI>
<SO>Modern Epidemiology</SO>
<YR>1998</YR>
<PG>250-2</PG>
<EN>2nd</EN>
<PB>Lippincott, Williams, Wilkins</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sesso-2008" MODIFIED="2013-09-10 20:09:24 +0100" MODIFIED_BY="[Empty name]" NAME="Sesso 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al</AU>
<TI>Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2008</YR>
<VL>300</VL>
<NO>18</NO>
<PG>2123-33</PG>
<IDENTIFIERS MODIFIED="2013-09-10 20:09:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1001/jama.2008.600"/>
<IDENTIFIER MODIFIED="2013-09-10 20:09:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18997197"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stone-1972" MODIFIED="2011-08-24 11:00:58 +0100" MODIFIED_BY="[Empty name]" NAME="Stone 1972" TYPE="BOOK">
<AU>Stone I</AU>
<SO>The Healing Factor. Vitamin C Against Disease</SO>
<YR>1972</YR>
<PB>Grosset &amp; Dunlap</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanaka-2000" MODIFIED="2013-09-10 20:11:25 +0100" MODIFIED_BY="[Empty name]" NAME="Tanaka 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tanaka H, Matsuda T, Miyagantani Y, Yukioka T, Matsuda H, Shimazaki S</AU>
<TI>Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study</TI>
<SO>Archives of Surgery</SO>
<YR>2000</YR>
<VL>135</VL>
<NO>3</NO>
<PG>326-31</PG>
<IDENTIFIERS MODIFIED="2013-09-10 20:11:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 20:11:10 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1001/archsurg.135.3.326"/>
<IDENTIFIER MODIFIED="2013-09-10 20:11:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10722036"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thwaites-2006" MODIFIED="2013-09-10 20:12:30 +0100" MODIFIED_BY="Harri Hemilä" NAME="Thwaites 2006" TYPE="JOURNAL_ARTICLE">
<AU>Thwaites CL, Yen LM, Glover C, Tuan PQ, Nga NT, Parry J, et al</AU>
<TI>Predicting the clinical outcome of tetanus: the tetanus severity score</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>3</NO>
<PG>279-87</PG>
<IDENTIFIERS MODIFIED="2013-09-10 20:12:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 20:12:30 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1365-3156.2006.01562.x"/>
<IDENTIFIER MODIFIED="2013-09-10 20:12:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16553907"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thwaites-2006a" MODIFIED="2013-09-10 20:13:51 +0100" MODIFIED_BY="Harri Hemilä" NAME="Thwaites 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Thwaites CL, Yen LM, Cordon SM, Binh NT, Nga N, White NJ, et al</AU>
<TI>Urinary catecholamine excretion in tetanus</TI>
<SO>Anaesthesia</SO>
<YR>2006</YR>
<VL>61</VL>
<NO>4</NO>
<PG>355-9</PG>
<IDENTIFIERS MODIFIED="2013-09-10 20:13:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 20:13:43 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1365-2044.2006.04580.x"/>
<IDENTIFIER MODIFIED="2013-09-10 20:13:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16548955"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wasay-2005" MODIFIED="2013-09-10 19:42:59 +0100" MODIFIED_BY="Harri Hemilä" NAME="Wasay 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wasay M, Khealani BA, Talati N, Shamsi R, Syed NA, Salahuddin N</AU>
<TI>Autonomic nervous system dysfunction predicts poor prognosis in patients with mild to moderate tetanus</TI>
<SO>BMC Neurology</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>1</NO>
<PG>2</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:42:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:42:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1471-2377-5-2"/>
<IDENTIFIER MODIFIED="2013-09-10 19:42:49 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15679900"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Webb-2007" MODIFIED="2013-09-10 19:41:46 +0100" MODIFIED_BY="[Empty name]" NAME="Webb 2007" TYPE="JOURNAL_ARTICLE">
<AU>Webb AL, Villamor E</AU>
<TI>Update: effects of antioxidant and non-antioxidant vitamin supplementation on immune function</TI>
<SO>Nutrition Reviews</SO>
<YR>2007</YR>
<VL>65</VL>
<NO>5</NO>
<PG>181-217</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:41:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:41:46 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1753-4887.2007.tb00298.x"/>
<IDENTIFIER MODIFIED="2013-09-10 19:41:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17566547"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-1999" MODIFIED="2013-06-04 11:54:43 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1999" TYPE="OTHER">
<AU>WHO</AU>
<TI>Recent outbreaks of scurvy. Scurvy and its prevention and control in major emergencies</TI>
<SO>WHO/NHD/99.11</SO>
<YR>1999</YR>
<PG>1-4 (Table 2)</PG>
<PB>WHO</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="http://whqlibdoc.who.int/hq/1999/WHO_NHD_99.11.pdf"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000" MODIFIED="2013-06-11 06:25:58 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2000" TYPE="OTHER">
<AU>WHO (World Health Organization)</AU>
<TI>Maternal and neonatal tetanus elimination by 2005</TI>
<SO>Annex C;</SO>
<YR>2000</YR>
<PG>27</PG>
<IDENTIFIERS MODIFIED="2013-06-04 12:06:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-04 12:06:50 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.unicef.org/health/files/MNTE_strategy_paper.pdf"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2013" MODIFIED="2013-06-11 06:31:50 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2013" TYPE="OTHER">
<AU>WHO (World Health Organization)</AU>
<TI>Tetanus</TI>
<SO>http://www.who.int/topics/tetanus/en/</SO>
<YR>2013</YR>
<IDENTIFIERS MODIFIED="2013-06-04 14:15:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Yuan-1997" MODIFIED="2013-09-10 19:40:58 +0100" MODIFIED_BY="[Empty name]" NAME="Yuan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Yuan L, Lau W, Thipphawong J, Kasenda M, Xie F, Bevilacqua J</AU>
<TI>Diphtheria and tetanus immunity among blood donors in Toronto</TI>
<SO>CMAJ</SO>
<YR>1997</YR>
<VL>156</VL>
<NO>7</NO>
<PG>985-90</PG>
<IDENTIFIERS MODIFIED="2013-09-10 19:40:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-10 19:40:58 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9099166"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-06-06 07:57:01 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Hemil_x00e4_-2008" MODIFIED="2013-06-04 12:08:55 +0100" MODIFIED_BY="[Empty name]" NAME="Hemilä 2008" TYPE="COCHRANE_REVIEW">
<AU>Hemilä H, Koivula T</AU>
<TI>Vitamin C for preventing and treating tetanus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-06-04 12:08:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-04 12:08:44 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006665.pub2"/>
<IDENTIFIER TYPE="PUBMED" VALUE="18425960"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2010" MODIFIED="2013-06-04 14:05:16 +0100" MODIFIED_BY="[Empty name]" NAME="Hemilä 2010" TYPE="COCHRANE_REVIEW">
<AU>Hemilä H, Koivula T</AU>
<TI>Vitamin C for preventing and treating tetanus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-06-04 14:05:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-04 14:05:16 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006665.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2011" MODIFIED="2013-06-06 07:57:01 +0100" MODIFIED_BY="[Empty name]" NAME="Hemilä 2011" TYPE="COCHRANE_REVIEW">
<AU>Hemilä H, Koivula T</AU>
<TI>Vitamin C for preventing and treating tetanus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2013-06-06 07:57:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006665.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-09-10 21:16:40 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-09-10 21:16:40 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-01-06 15:58:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jahan-1984">
<CHAR_METHODS MODIFIED="2010-01-06 15:58:15 +0000" MODIFIED_BY="[Empty name]">
<P>Non randomised; allocation method not described.<BR/>Vitamin C and control participants treated in separate wards.<BR/>No placebo; no blinding.<BR/>Duration up to 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>117 tetanus patients admitted to the Infectious Disease Hospital, Dhaka, Bangladesh.<BR/>Age group 1 to 12 years: 31 vitamin C, 31 control.<BR/>Age group 13 to 30 years: 27 vitamin C, 28 control.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-30 11:50:46 +0000" MODIFIED_BY="Harri Hemilä">
<P>Vitamin C intravenously 1 g/day vs. no vitamin C. Both groups received standard treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 15:58:16 +0000" MODIFIED_BY="[Empty name]">
<P>Case fatality rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-06 15:58:20 +0000" MODIFIED_BY="[Empty name]">
<P>Poorly described trial (see <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>).<BR/>Additional information was received from the first author, Professor Jahan.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-06-12 15:03:36 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-09-10 21:16:40 +0100" MODIFIED_BY="Harri Hemilä">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-09-10 21:16:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-10 21:16:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jahan-1984">
<DESCRIPTION>
<P>"we selected two wards side by side. Patients of one ward were under treatment with vitamin C in addition to conventional treatments. In another ward patients were enrolled as a control group and got only the conventional treatment (without vitamin C)". Personal communication with trial author. No randomisation took place.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-09-06 08:42:53 +0100" MODIFIED_BY="Harri Hemilä" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-06 08:42:53 +0100" MODIFIED_BY="Harri Hemilä" RESULT="NO" STUDY_ID="STD-Jahan-1984">
<DESCRIPTION>
<P>Allocation method not described, see above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-06-06 07:26:25 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-06-06 07:26:15 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-06 07:26:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jahan-1984">
<DESCRIPTION>
<P>Patients in one ward were administered vitamin C and patients in another ward served as control. This was known to personnel but it is not clear whether it was known to the patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-06-06 07:30:59 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-06 07:30:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jahan-1984">
<DESCRIPTION>
<P>Mortality in a hospital is not biased by subjective observations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-06-06 07:24:53 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-06 07:24:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jahan-1984">
<DESCRIPTION>
<P>No drop outs according to the report</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-06-06 07:31:12 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-09-10 21:15:01 +0100" MODIFIED_BY="Harri Hemilä">
<COMPARISON ID="CMP-001" MODIFIED="2013-09-10 21:15:01 +0100" MODIFIED_BY="Harri Hemilä" NO="1">
<NAME>Vitamin C vs control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2013-09-10 21:15:01 +0100" MODIFIED_BY="Harri Hemilä" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="38.8217879300869" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Case fatality rate</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin C</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="23" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>aged 1 to 12 years</NAME>
<DICH_DATA CI_END="0.12172638993986416" CI_START="0.015757626666491577" EFFECT_SIZE="0.0437963355559818" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="23" LOG_CI_END="-0.9146152577369516" LOG_CI_START="-1.8025091931449313" LOG_EFFECT_SIZE="-1.3585622254409415" ORDER="4602" O_E="-11.5" SE="0.5215532928045115" STUDY_ID="STD-Jahan-1984" TOTAL_1="31" TOTAL_2="31" VAR="3.676229508196722" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="19" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>aged 13 to 30 years</NAME>
<DICH_DATA CI_END="0.8480677670880609" CI_START="0.10401623366523387" EFFECT_SIZE="0.29700642253221543" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.07156944291251674" LOG_CI_START="-0.9828988756911536" LOG_EFFECT_SIZE="-0.5272341593018351" ORDER="4603" O_E="-4.236363636363636" SE="0.5353194199676186" STUDY_ID="STD-Jahan-1984" TOTAL_1="27" TOTAL_2="28" VAR="3.489586776859504" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-09-10 21:15:02 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-09-10 21:15:02 +0100" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Effect of vitamin C on tetanus case fatality rate by age groups in <LINK REF="STD-Jahan-1984" TYPE="STUDY">Jahan 1984</LINK>
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAnoAAACwCAMAAACvmDPFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-05-22 12:24:27 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-05-22 12:24:27 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-05-22 12:24:27 +0100" MODIFIED_BY="[Empty name]">Search methods for the second review update (2011)</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-22 12:24:11 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches  </HEADING>
<P>For an outline of the search methods used in first update of this review see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>For this second update the following databases and dates are covered:</P>
<UL>
<LI>Cochrane Wounds Group Specialised Register (searched 4 August 2011);</LI>
<LI>Cochrane Infectious Diseases Group Specialised Register (searched 24 August 2011);</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2011, Issue 3);</LI>
<LI>Ovid MEDLINE  (1950 to August Week 2 2011);</LI>
<LI>Ovid MEDLINE (In-Process &amp; Other Non-Indexed Citations August 18, 2011);</LI>
<LI>Ovid EMBASE (2009 to 2010 Week 50)</LI>
</UL>
<P>The following strategy was used to search The Cochrane Central Register of Controlled Trials (CENTRAL):<BR/>#1 MeSH descriptor Tetanus explode all trees<BR/>#2 tetanus<BR/>#3 (#1 OR #2)<BR/>#4 MeSH descriptor Ascorbic Acid explode all trees<BR/>#5 ascorb* or "vitamin C"<BR/>#6 (#4 OR #5)<BR/>#7 (#3 AND #6)</P>
<P>The search strategies for Ovid MEDLINE and Ovid EMBASE can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> respectively. No methodological filters were used. No date or language restrictions were applied.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Searching other resources  </HEADING>
<P>Previously, <LINK REF="REF-Briggs-1984" TYPE="REFERENCE">Briggs 1984</LINK> carried out extensive literature searches and published a bibliography containing over 400 references to papers related to vitamin C and infections, which we checked. We also searched the reference lists of all other pertinent reviews and of the potentially eligible studies identified in our search.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-12-17 18:12:20 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-12-17 18:10:39 +0000" MODIFIED_BY="[Empty name]">Ovid MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-12-17 18:10:06 +0000" MODIFIED_BY="[Empty name]">
<P>1 exp Tetanus/<BR/>2 exp Tetanus Toxin/<BR/>3 exp Tetanus Toxoid/<BR/>4 tetanus.mp.<BR/>5 or/1-4<BR/>6 exp Ascorbic Acid/<BR/>7 ascorb$.mp.<BR/>8 (vitamin$ adj5 C).mp.<BR/>9 or/6-8<BR/>10 5 and 9</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-12-17 18:12:20 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-12-17 18:10:58 +0000" MODIFIED_BY="[Empty name]">Ovid EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-12-17 18:11:34 +0000" MODIFIED_BY="[Empty name]">
<P>1 exp Tetanus/ <BR/>2 exp Tetanus Toxin/ <BR/>3 exp Tetanus Toxoid/ <BR/>4 tetanus.mp. <BR/>5 or/1-4 <BR/>6 exp Ascorbic Acid/ <BR/>7 ascorb$.mp. <BR/>8 (vitamin$ adj5 C).mp. <BR/>9 or/6-8 <BR/>10 5 and 9</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>